PDL BioPharma, Inc.
PDLI
PDLI was delisted on the 30th of December, 2020.
233 hedge funds and large institutions have $1.18B invested in PDL BioPharma, Inc. in 2014 Q1 according to their latest regulatory filings, with 34 funds opening new positions, 93 increasing their positions, 68 reducing their positions, and 24 closing their positions.
397% more call options, than puts
Call options by funds: $12.7M | Put options by funds: $2.55M
42% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 24
37% more repeat investments, than reductions
Existing positions increased: 93 | Existing positions reduced: 68
4% more funds holding
Funds holding: 224 → 233 (+9)
1% more capital invested
Capital invested by funds: $1.17B → $1.18B (+$8.69M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| 1 |
Schroder Investment Management Group
London,
United Kingdom
|
+$31.5M |
| 2 |
Wells Fargo
San Francisco,
California
|
+$17.6M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$10.4M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
+$10.4M |
| 5 |
Two Sigma Investments
New York
|
+$9.96M |
Top Sellers
| 1 |
GAM
Gotham Asset Management
New York
|
-$14.4M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$8.09M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$7.7M |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$7.65M |
| 5 |
JP Morgan Chase
New York
|
-$6.95M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
EWM
251
Elite Wealth Management
Kirkland,
Washington
| – | -$13K | -1,500 | Closed |
|
|
HF
252
Hoxton Financial
Shepherdstown,
West Virginia
| – | -$12K | -1,398 | Closed |
|
|
SSG
253
Summit Securities Group
New York
| – | -$8K | -1,000 | Closed |
|
254
Envestnet Asset Management
Chicago,
Illinois
| – | -$3K | -316 | Closed |
|
|
PG
255
PEAK6 Group
Chicago,
Illinois
| – | -$2.57K | -300 | Closed |
|
|
BWFA
256
Baltimore-Washington Financial Advisors
Columbia,
Maryland
| – | -$1K | -62 | Closed |
|
PDLI Hedge Fund Activity: Q1 2014 in Review
233 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in PDL BioPharma, Inc. (PDLI) for Q1 2014, worth a combined $1.18B — up 0.74% from $1.17B a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new PDLI positions and 24 closed out — a net gain of 10 holders — while 93 added to existing stakes and 68 trimmed.
The largest buyer was Schroder Investment Management Group, adding an estimated $31.5M. The largest seller was Gotham Asset Management, cutting an estimated $14.4M.
- 233 institutional investors held PDL BioPharma, Inc. (PDLI) as of Q1 2014, up from 224 in Q4 2013.
- Funds reported $1.18B of PDL BioPharma, Inc. stock for Q1 2014, up 0.74% quarter-over-quarter.
- 34 funds opened new PDL BioPharma, Inc. positions in Q1 2014 and 24 closed out, a net change of +10 holders.
- The largest PDL BioPharma, Inc. buyer in Q1 2014 was Schroder Investment Management Group, an estimated $31.5M added.
- The largest PDL BioPharma, Inc. seller in Q1 2014 was Gotham Asset Management, an estimated $14.4M sold.
Based on aggregated 13F filings for Q1 2014.